ALLMedicine™ Hepatitis B Center

Jun 2nd, 2021 - Entecavir (ETV) is a widely used anti-hepatitis B virus (HBV) drug. However, the emergence of resistant mutations in HBV reverse transcriptase (RT) results in treatment failure. To understand the mechanism underlying the development of ETV-resista...

Jun 2nd, 2021 - The neutrophil-to-lymphocyte ratio (NLR) has been reported as a prognostic marker of hepatocellular carcinoma (HCC); however, the relationship between NLR and risk of HCC occurrence has yet to be systematically elucidated. We aimed to investigate ...

Jun 2nd, 2021 - Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch. ETV-treated (≥12 months) chr...

Jun 2nd, 2021 - Chronic hepatitis B is associated with important morbidity and mortality. Inflammation has a pivotal role in hepatic fibrosis of this population. Hemogram-derived inflammatory predictors, such as mean platelet volume (MPV) and platelet to lymphocy...

Jun 1st, 2021 - Background: The immunogenicity against hepatitis B vaccine is unsatisfactory in the chronic kidney disease (CKD) patients, and studies evaluating augmented vaccine regimens to enhance immunogenicity have been inconclusive.Objectives: To evaluate t...

Apr 15th, 2021 - Screening for Hepatitis B Virus Infection in Adolescents and Adults: Recommendation Statement.|2021||blood,diagnosis,prevention & control,blood,diagnosis,prevention & control,

Jan 20th, 2021 - Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepa...

Jan 4th, 2021 - Primary liver cancer has the sixth highest incidence and fourth highest cancer mortality worldwide. Hepatitis B is the leading cause of liver cancer, though its incidence is decreasing with vaccination. Alcohol is the leading cause of liver transp...

Dec 15th, 2020 - An estimated 862 000 persons in the US are living with chronic infection with hepatitis B virus (HBV). Persons born in regions with a prevalence of HBV infection of 2% or greater, such as countries in Africa and Asia, the Pacific Islands, and part...

Jul 27th, 2020 - This Provisional Clinical Opinion update presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management. All patients anticipating systemic anticancer therapy should be tested for HBV by 3 tests-hepatitis B surface an...

Jun 8th, 2021 - A nationwide analysis of over 2.5 million Scottish adults who received a first dose of the Oxford/AstraZeneca or Pfizer/BioNTech vaccine between December 2020 and April 2021 has confirmed a small increased risk of immune thrombocytopenic purpura (...

Jun 2nd, 2021 - Entecavir (ETV) is a widely used anti-hepatitis B virus (HBV) drug. However, the emergence of resistant mutations in HBV reverse transcriptase (RT) results in treatment failure. To understand the mechanism underlying the development of ETV-resista...

Jun 2nd, 2021 - The neutrophil-to-lymphocyte ratio (NLR) has been reported as a prognostic marker of hepatocellular carcinoma (HCC); however, the relationship between NLR and risk of HCC occurrence has yet to be systematically elucidated. We aimed to investigate ...

Jun 2nd, 2021 - Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch. ETV-treated (≥12 months) chr...

Jun 2nd, 2021 - Chronic hepatitis B is associated with important morbidity and mortality. Inflammation has a pivotal role in hepatic fibrosis of this population. Hemogram-derived inflammatory predictors, such as mean platelet volume (MPV) and platelet to lymphocy...

Jun 8th, 2021 - A nationwide analysis of over 2.5 million Scottish adults who received a first dose of the Oxford/AstraZeneca or Pfizer/BioNTech vaccine between December 2020 and April 2021 has confirmed a small increased risk of immune thrombocytopenic purpura (...

May 31st, 2021 - NEW YORK (Reuters Health) - A tri-antigenic hepatitis B vaccine (TAV) effectively prevented hepatitis B virus (HBV) infection in adults, was somewhat more effective than a mono-antigenic vaccine (MAV) comparator, but had higher side effect rates i...

Apr 26th, 2021 - BEIJING (Reuters) - China's SciClone Pharmaceuticals has begun a clinical trial to test if its hepatitis B treatment Zadaxin helps to boost immunity provided by COVID-19 vaccines, it said on Monday. SciClone said it is using an inactivated COVID-1...

Apr 1st, 2021 - These days deciding when to stop targeted treatment for chronic hepatitis B is a bigger challenge than knowing when to start, Norah A. Terrault, MD, MPH, observed at the Gastroenterology Updates, IBD, Liver Disease Conference. That's because the t...

Feb 2nd, 2021 - NEW YORK (Reuters Health) - The United States has made progress in identifying infants born to hepatitis B surface antigen (HBsAg)-positive women and getting them vaccinated. Yet, there is also substantial room for improvement, including closing t...